Tomahawk, WI 02/19/2014 (BasicsMedia) – Markets and analysts eyes are all set on Mylan Inc. (NASDAQ:MYL) which is scheduled to announce its fourth quarter financial results on February 27, 2014 amidst various issues ranging from recalling of drugs made by its subsidiaries to alleged rumors of its merger with Teva Pharmaceuticals Pvt. Ltd.. Mylan, right now, is a stock to concentrate on because of its growing presence in Indian market and its capability to produce various important and helpful drugs.

Market recall of drugs

Mylan Inc. (NASDAQ:MYL)’s subsidiary Agila Specialties Private Limited has undertaken a voluntary nationwide recall of 10 lots of its Etomidate Injection because they have reason to believe that the individual vials of the 10 lots may contain small black particles which are identified as paper shipper labels and there are chances that these lots have illegible or missing lot numbers and expiry dates printed on the outer carton of the said lots. These vials had been produced at Agila’s Warsaw plant in Poland and they bear a Pfizer label. Neither Mylan nor Pfizer has received any complaint regarding adverse effects of the said injection but as a precaution these lots are being recalled as intravenous administration of above mentioned particles may lead to impairment of microcirculation, phlebitis, infection, embolism and subsequent infarction. Mylan shares were trading low after news of the drug recall reached the markets.

Mylan in India

Mylan Inc. (NASDAQ:MYL)’s Indian subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.’s (NASDAQ:GILD) exclusive branded medicines business partner for India whereby Mylan has been given the exclusive marketing and distribution rights of Gilead’s many drugs in India. Mylan and Gilead have been in partnership since 2006 for marketing and distribution of many Gilead’s medicines and injections in India and this agreement has further taken their collaboration to a new level. Mylan’s CEO, Heather Bresch, commented on this deal that, “This further extension of our collaboration with Gilead builds off of our existing successful partnership manufacturing and supplying high-quality, cost-effective generic antiretroviral therapy for those in resource challenged countries, delivering on our mission of providing access to high quality medicine to the world’s seven billion people.” Mylan Inc. (NASDAQ:MYL)’s Indian subsidiary has recently launched their first trastuzumab biosimilar in India which will be marketed by them under their brand name HertrazTM and which is intended for the treatment of HER2-positive metastatic breast cancer.

Conclusion

Mylan Inc. (NASDAQ:MYL), as a stock has been kept as a “buy” by many analysts who have undying faith in Mylan’s drug producing ability and its capability to market its products. Only coming weeks shall reveal that Mylan’s fourth quarter financial results will exceed analysts’ prediction or will terribly fail them till then Mylan’s stock is a “wait and watch”!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.